Notice of Clarification for PAS-21-245 Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
Notice Number:
NOT-AR-22-021

Key Dates

Release Date:

May 9, 2022

Related Announcements

PAS-21-245 - Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this notice is to clarify the “Applications Not Responsive to the FOA” statement (below) in Funding Opportunity Announcement (FOA) PAS-21-245, "Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)":

Currently Reads:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Applications Not Responsive to the FOA

The proposed study must contain two or more vesicants, because the emphasis is to understand the common mechanisms by which these vesicants cause skin injury. If an application proposes studying only one chemical, it is not responsive to the FOA.

Non-responsive applications will be returned without review.

See Section VIII. Other Information for award authorities and regulations.

Modified to Read (changes shown in bold italics:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Applications Not Responsive to the FOA

The proposed study must contain two or more vesicants, because the emphasis is to understand the common mechanisms by which these vesicants cause skin injury. If an application proposes studying only one chemical, it is not responsive to the FOA.

By two or more vesicants, we mean that the vesicants belong to different chemical categories, e.g., mustard (sulfur, nitrogen, 2-chloroethyl ethylsulfide or CEES), Lewisite, phosgene oxime, and arsenicals are considered as distinct vesicants.

Sulfur and nitrogen mustard and 2-chloroethyl ethylsulfide (CEES) are viewed as in the same chemical category for this FOA. Proposals to study only these three mustard analogs will be viewed as studying one vesicant, hence not responsive to this FOA.

We encourage the potential applicants to consult with the program officials assigned to this FOA to be sure that their applications are responsive in this regard.

See Section VIII. Other Information for award authorities and regulations.

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Hung Tseng PhD
National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-496-0810
Email: tsengh@mail.nih.gov
 

Dave Yeung, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: dy70v@nih.gov